ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Intercept Pharmaceuticals, Inc. (ICPT) stock surged +0.21%, trading at $19.00 on NASDAQ, up from the previous close of $18.96. The stock opened at $19.00, fluctuating between $18.98 and $19.01 in the recent session.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Employees | 341 |
Beta | 0.88 |
Sales or Revenue | $285.71M |
5Y Sales Change% | 1% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |